Sandoz Launches Ranluspec Biosimilar In Europe

By Reuters News

- SANDOZ GROUP AG SDZ.S:

  • SANDOZ LAUNCHES RANLUSPEC® (RANIBIZUMAB) IN EUROPE, PROVIDING AN AFFORDABLE TREATMENT OPTION FOR PATIENTS WITH RETINAL DISEASES

  • RANLUSPEC APPROVED BY EUROPEAN COMMISSION IN FEBRUARY 2026

  • RANLUSPEC HAS EQUIVALENT EFFICACY AND COMPARABLE SAFETY TO LUCENTIS

  • HOLDS EXCLUSIVE RIGHTS FOR RANLUSPEC IN EU EXCLUDING GERMANY

  • COMMERCIALISES EPRUVY (RANIBIZUMAB) IN GERMANY UNDER SEPARATE AGREEMENT

  • RANLUSPEC COMMERCIALISED BY SANDOZ IN EU EXCLUDING GERMANY

Further company coverage: SDZ.S

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk